home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

NO End To Protein Modification

  October, 3 2007 9:06
your information resource in human molecular genetics
A new biological signalling molecule is described online in Nature Chemical Biology. Nitric oxide, or NO, is a common messenger in biological systems and produces a variety of physiological responses, but the precise signalling pathways involved have so far remained unclear.

Takaaki Akaike and colleagues now show that cellular NO production produces a 'nitrated' second messenger called 8-nitro-cGMP, which bears a chemical resemblance to a known signalling molecule, cyclic GMP (cGMP). Because of this similarity, 8-nitro-cGMP is a good mimic and can activate several of cGMP's standard signalling pathways. However 8-nitro-cGMP has a number of additional functions including the ability to tag proteins with a cGMP tag. The discovery of these new pathways and modifications provides new insights into NO physiology and pathological responses.

Author contact:

Takaaki Akaike (Kumamoto University, Japan)

E-mail: takakaik@gpo.kumamoto-u.ac.jp

Abstract available online.

(C) Nature Chemical Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.